Hangzhou Tigermed Consulting stock | 2026 forecast, price target & growth

Hangzhou Tigermed Co...

SZSE:300347

¥ 55,80

¥-0,24 (-0,43%)

55,80 ¥

¥-0,24 (-0,43%)

End-of-day quote: 04/09/2026

Hangzhou Tigermed Consulting Stock Value

The analyst rating for SZSE:300347 is currently Outperform.

Outperform

Hangzhou Tigermed Consulting Company Info

EPS Growth 5Y

5,71%

Market Cap

¥45,30 B

Long-Term Debt

¥0,32 B

Annual earnings

N/A

Dividend

¥0,12

Dividend Yield

0,22%

Founded

2004

Industry

Health Care

Country

China

Website

Hangzhou Tigermed Consulting

ISIN Number

CNE100001KV8

Website

http://www.tigermedgrp.com

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

¥67,40

20.79%

Last Update: 04/10/2026

Analysts: 15

Highest Price Target ¥79,25

Average Price Target ¥67,40

Lowest Price Target ¥44,00

In the last five quarters, Hangzhou Tigermed Consulting’s Price Target has fallen from ¥103,16 to ¥95,38 - a -7,54% decrease. Fourteen analysts predict that Hangzhou Tigermed Consulting’s share price will increase in the coming year, reaching ¥67,40. This would represent an increase of 20,79%.

Top growth stocks in the health care sector (5Y.)

What does Hangzhou Tigermed Consulting do?

Hangzhou Tigermed Consulting Co., Ltd. is a player in the life sciences and clinical research industry, providing a wide range of services and solutions to pharmaceutical, biotechnology, and medical device companies globally. The company has established a reputation for its clinical trial solutions, pharmacovigilance services, and other related offerings, which are designed to optimize and accelerate the development process of new therapies and products. Business Segments The company operates...

Business Segments

The company operates across several key business segments that cover a diverse range of services, primarily categorized into Clinical Trial Solutions (CTS), Clinical-related and Laboratory Services (CRLS), Pharmacovigilance (PV), and Real World Evidence (RWE) solutions.

Clinical Trial Solutions (CTS): This segment focuses on providing comprehensive services related to the design, management, and execution of clinical trials. The company specializes in recruitment strategies, study management, and regulatory affairs, ensuring that trials meet national and international regulatory requirements.

Clinical-related and Laboratory Services (CRLS): The CRLS segment offers essential support services for clinical research and includes data management, statistical analysis, and laboratory services. With a dedicated team of professionals, the company manages a substantial volume of lab projects, enhancing the efficiency of clinical trials through statistical methodologies and data management techniques.

Pharmacovigilance (PV): The company’s pharmacovigilance services encompass a full life-cycle management approach. The company ensures that safety issues and adverse events are adequately monitored and reported, helping pharmaceutical clients comply with strict regulatory standards. A global pharmacovigilance team facilitates real-time monitoring, data collection, and analysis to maintain drug safety post-market authorization.

Real World Evidence (RWE): This segment focuses on collecting and analyzing data from real-world practice to provide insights into treatment effectiveness, patient outcomes, and healthcare utilization. The company’s RWE services leverage its extensive network and technology to conduct observational studies that inform clinical guidelines and decision-making.

Business Strategy

The company's strategy leverages its expertise in the life sciences sector to position itself as a leader in clinical development and research services. By focusing on service delivery, operational efficiency, and deep industry knowledge, the company aims to enhance client satisfaction and build long-lasting partnerships with stakeholders in the healthcare sector.

Innovation is at the core of the company’s strategy, driving it to develop solutions that streamline clinical operations, optimize data management processes, and improve the overall efficiency of clinical trials. The company is committed to continuous improvement and is guided by its mission to advance healthcare through research.

The company also seeks to expand its global presence and reach, entering new markets and strengthening its service capabilities to offer a complete suite of clinical research services worldwide. The dedication to research outputs and maintaining rigorous compliance standards reflects the company's ambition to be a reliable partner for clients engaged in the complex drug development process.

Products and Services

The company provides an extensive array of products and services designed to support research and development throughout the clinical trial process.

Clinical Trial Management: Full-service management of clinical trials, including feasibility studies, patient recruitment, site management, and regulatory submissions.

Data Management and Statistical Services: Advanced data management solutions encompassing data collection, storage, and analysis to ensure integrity and compliance with statistical standards.

Laboratory Services: Provision of laboratory support including biomarker analysis, sample processing, and bioanalytical services that meet Good Laboratory Practice (GLP) standards.

Pharmacovigilance Services: Comprehensive safety monitoring services to ensure that all products are closely monitored post-approval, allowing for the collection of post-market safety data and proactive risk management.

Real World Evidence Solutions: Services aimed at collecting and analyzing real-world data to enrich clinical understanding of new products and inform healthcare decisions.

Regulatory Affairs Consulting: Expertise in navigating complex regulatory environments to support clients in obtaining necessary approvals for their products.

Geographical Markets Served

The company operates in multiple geographical markets, with a significant presence in China and expanding footprints across Asia Pacific, Europe, Latin America, and Africa. The company’s diverse geographical presence enables it to serve a broad clientele, offering localized support while adhering to international regulatory standards.

Customers

The company serves a diverse array of customers across various sectors, primarily comprising multinational pharmaceutical companies, biotechnology firms, and medical device manufacturers. With over 100 global customers, including many leading multinational corporations, the company has established itself as a trusted partner in the clinical research arena.

Sales and Marketing

The company employs a multifaceted approach to sales and marketing, leveraging digital marketing strategies, industry conferences, client referrals, and direct sales teams to reach potential clients. The marketing efforts focus on highlighting the company’s unique capabilities, service quality, and successful project outcomes to attract new business and strengthen existing relationships.

History

Hangzhou Tigermed Consulting Co., Ltd was founded in 2004. The company was incorporated in 2004.

Hangzhou Tigermed Consulting Questions and Answers

Which sectors generate sales and which are the top 3 markets?

**Revenue distribution by industry:** - **Pharmaceutical Industry:** approx. 60% - **Biotechnology:** approx. 25% - **Medical Devices:** approx. 15% **TOP 3 markets and their percentage shares:** - **China:** approx. 50% - **USA:** approx. 30% - **Europe:** approx. 15% Hangzhou Tigermed Consulting...

At which locations are the company’s products manufactured?

**Production Sites:** Mainly in China Hangzhou Tigermed Consulting Co., Ltd is a leading company in the field of clinical research services. The company does not produce physical products in the traditional sense, as it focuses on services in the field of clinical research and development. The mai...

What strategy does Hangzhou Tigermed Consulting pursue for future growth?

**Revenue Growth:** Estimated 10-12% annually (2025-2027) **Strategic Focus Areas:** 1. **International Expansion:** Hangzhou Tigermed Consulting Co., Ltd is strongly focused on expanding its international presence, particularly in the USA and Europe. This is intended to be achieved through strateg...

Which raw materials are imported and from which countries?

**Imported Raw Materials/Supplies:** Clinical trial materials, laboratory equipment, IT services **Countries of Origin:** USA, Germany, Japan Hangzhou Tigermed Consulting Co., Ltd is a leading company in the field of clinical research services. The company mainly imports clinical trial materials a...

How strong is the company’s competitive advantage?

**Market share in China:** 12% (2024) **R&D expenses:** 8% of revenue (2024) **Customer satisfaction rate:** 90% (2023) Hangzhou Tigermed Consulting Co., Ltd has a significant competitive advantage in the field of clinical research services, especially in China. With a market share of 12% in 20...

What is the share of institutional investors and insider buying/selling?

**Institutional Investor Share:** approximately 45% (estimated 2025) **Insider Buys/Sells:** No significant changes in the last year (estimated 2025) The institutional investor share in Hangzhou Tigermed Consulting Co., Ltd is estimated to be around 45%. This reflects the confidence of institutio...

What percentage market share does Hangzhou Tigermed Consulting have?

**Market share of Hangzhou Tigermed Consulting Co., Ltd:** 12% (2025, estimated) **Top competitors and their market shares:** 1. **IQVIA Holdings Inc.:** 18% 2. **Labcorp Drug Development:** 15% 3. **Syneos Health Inc.:** 14% 4. **Hangzhou Tigermed Consulting Co., Ltd:** 12% 5. **Parexel Internatio...

Is Hangzhou Tigermed Consulting stock currently a good investment?

**Revenue Growth:** 18% (2024) **Profit Growth:** 15% (2024) **Market Share in the Asian CRO Market:** 10% (2024) Hangzhou Tigermed Consulting Co., Ltd recorded solid revenue growth of 18% in 2024, attributed to increased demand for clinical research services and expansion into new markets. The...

Does Hangzhou Tigermed Consulting pay a dividend – and how reliable is the payout?

**Dividend Yield:** 1.5% (estimated for 2025) **Dividend History:** Continuous payout for several years Hangzhou Tigermed Consulting Co., Ltd has regularly distributed dividends in recent years, indicating a reliable dividend policy. The estimated dividend yield for 2025 is around 1.5%, based on...

New support ticket

Explore

Hangzhou Tigermed Consulting Stock Value

Hangzhou Tigermed Consulting Company Info

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does Hangzhou Tigermed Consulting do?

Hangzhou Tigermed Consulting Questions and Answers

Offer & Services

Service & Collaboration

Company & Legal

New support ticket

Explore

Hangzhou Tigermed Consulting Stock Value

Hangzhou Tigermed Consulting Company Info

Analyst Price Target The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does Hangzhou Tigermed Consulting do?

Hangzhou Tigermed Consulting Questions and Answers

Offer & Services

Service & Collaboration

Company & Legal

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.